Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03335553 · ClinicalTrials.gov registry record · Phase 1
A Study of Experimental Medication BMS-986235 in Healthy Subjects
A Phase 1 study of Mediators of Inflammation, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 122
- Enrollment target
- 2
- Study locations
NCT03335553: Completed Phase 1 study of Mediators of Inflammation, sponsored by Bristol-Myers Squibb.
NCT03335553 is a Phase 1 study of Mediators of Inflammation that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 122 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (103% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03335553, a Phase 1 study of Mediators of Inflammation, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 122 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a study of experimental medication BMS-986235 in healthy subjects.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG BMS-986235
Study Locations (2)
California
- Anaheim Clinical Trials - Anaheim
Utah
- PRA Health Sciences - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2017-11-15 |
| Est. Completion | 2021-07-02 |
| Phase | Phase 1 |
What the finished NCT03335553 record still lists
NCT03335553 is an interventional study that assigns participants to a tested intervention. The registered 122 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (103% higher).
The record links to 1 condition, with Mediators of Inflammation appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03335553 reports a single indexed study location in California, Utah.
Frequently Asked Questions
What is clinical trial NCT03335553 about?
NCT03335553 is a clinical study titled "A Study of Experimental Medication BMS-986235 in Healthy Subjects". This is a study of experimental medication BMS-986235 in healthy subjects.
What is the current status of trial NCT03335553?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 122 participants. The study started on 2017-11-15. Estimated completion is 2021-07-02.
What conditions does trial NCT03335553 study?
This clinical trial studies the following conditions: Mediators of Inflammation.
What interventions are being tested in trial NCT03335553?
The interventions under investigation include: Placebo (OTHER), BMS-986235 (DRUG).
Who is sponsoring clinical trial NCT03335553?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03335553 being conducted?
This trial has 2 study locations across California, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03335553's enrollment target sits among peer trials
122 475th of 2000 higher than 1,525 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03363373 · 122 participants · Phase 2
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
- NCT03463954 · 122 participants · NA
Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors
- NCT04503265 · 122 participants · Phase 1
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
- NCT04700527 · 122 participants · Phase 1
The Effects of SCFA Supplementation in Subjects Receiving Abdominopelvic RT: A Randomized Controlled Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI